Andros Pharmaceuticals announced on the 30th that its new drug, APC201, for treating knee osteoarthritis is progressing smoothly in its Phase II clinical trial in Australia. The company has already enrolled over 85% of participants, with the goal of completing the full enrollment by the end of this year. Preliminary data is expected to be available in the first quarter of next year. Based on these results, Andros plans to initiate a global multi-center Phase III clinical trial and explore international licensing and collaboration opportunities.
Read more
